MA49704A - Dérivés d'acide biliaire à marquage isotopique - Google Patents

Dérivés d'acide biliaire à marquage isotopique

Info

Publication number
MA49704A
MA49704A MA049704A MA49704A MA49704A MA 49704 A MA49704 A MA 49704A MA 049704 A MA049704 A MA 049704A MA 49704 A MA49704 A MA 49704A MA 49704 A MA49704 A MA 49704A
Authority
MA
Morocco
Prior art keywords
isotopic
labeled
acid derivatives
biliary acid
biliary
Prior art date
Application number
MA049704A
Other languages
English (en)
Inventor
Gabriel Galvin
Kevin Schaab
Matthew Yanik
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MA49704A publication Critical patent/MA49704A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005Glycosides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA049704A 2017-07-24 2018-07-23 Dérivés d'acide biliaire à marquage isotopique MA49704A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762536326P 2017-07-24 2017-07-24
US201762536609P 2017-07-25 2017-07-25

Publications (1)

Publication Number Publication Date
MA49704A true MA49704A (fr) 2021-03-31

Family

ID=65041285

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049704A MA49704A (fr) 2017-07-24 2018-07-23 Dérivés d'acide biliaire à marquage isotopique

Country Status (12)

Country Link
US (2) US11472831B2 (fr)
EP (1) EP3658150A4 (fr)
JP (1) JP2020528892A (fr)
KR (1) KR20200031145A (fr)
CN (1) CN111050772A (fr)
AU (1) AU2018307611A1 (fr)
BR (1) BR112020001362A2 (fr)
CA (1) CA3070837A1 (fr)
IL (1) IL272119A (fr)
MA (1) MA49704A (fr)
MX (1) MX2020000873A (fr)
WO (1) WO2019023103A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202021595A (zh) 2018-08-10 2020-06-16 德商菲尼克斯製藥股份有限公司 用於預防及治療困難梭狀芽孢桿菌關聯疾病之異石膽酸或異別石膽酸及其氘化衍生物
US20230146782A1 (en) * 2019-08-06 2023-05-11 Du Jessica Xinyun Deoxycholic acid compounds, pharmaceutical compositions and uses thereof
CN112898369B (zh) * 2019-12-04 2024-09-17 博瑞生物医药(苏州)股份有限公司 用于制备奥贝胆酸的方法
JP7755328B2 (ja) * 2021-09-09 2025-10-16 国立大学法人九州大学 重水素富化組成物、重水素置換されたカルボン酸の製造方法、反応促進剤及びカルボン酸を酸無水物に変換する化合物の使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10113257C1 (de) 2001-03-19 2002-11-14 Inst Mikrotechnik Mainz Gmbh Elektrophoresevorrichtung und ihre Verwendung
DK2040713T3 (da) 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
SG10201400162QA (en) 2008-11-19 2014-05-29 Intercept Pharmaceuticals Inc Tgr5 modulators and methods of use thereof
WO2013037482A1 (fr) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer
SG10201607230SA (en) 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
BR112015009395A2 (pt) * 2012-10-26 2017-07-04 Intercept Pharmaceuticals Inc processo para preparação de derivados do ácido biliar
DK2997035T3 (en) 2013-05-14 2018-07-02 Intercept Pharmaceuticals Inc 11-HYDROXY-6-SUBSTITUTED BALIC ACID DERIVATIVES AND AMINO ACID CONJUGATES THEREOF AS FARNESOID X RECEPTOR MODULATORS
US20150112089A1 (en) 2013-10-22 2015-04-23 Metselex, Inc. Deuterated bile acids
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
WO2016168553A1 (fr) * 2015-04-17 2016-10-20 Concert Pharmaceuticals, Inc. Acide obéticholique deutéré
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN108348530B (zh) 2015-10-07 2023-09-29 英特塞普特医药品公司 法尼醇x受体调节剂
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN109467585A (zh) 2016-03-11 2019-03-15 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物

Also Published As

Publication number Publication date
WO2019023103A1 (fr) 2019-01-31
CN111050772A (zh) 2020-04-21
EP3658150A4 (fr) 2021-03-31
MX2020000873A (es) 2020-07-22
AU2018307611A1 (en) 2020-02-06
US20200165290A1 (en) 2020-05-28
US20230057232A1 (en) 2023-02-23
IL272119A (en) 2020-03-31
KR20200031145A (ko) 2020-03-23
JP2020528892A (ja) 2020-10-01
CA3070837A1 (fr) 2019-01-31
US11472831B2 (en) 2022-10-18
BR112020001362A2 (pt) 2020-08-11
EP3658150A1 (fr) 2020-06-03

Similar Documents

Publication Publication Date Title
MA49421A (fr) Formulations d'arn
EP3517528A4 (fr) Sel d'addition d'acide de dérivé de benzimidazole
EP3277381C0 (fr) Dérivés de nitrobenzyle d'agents anticancéreux
EP3443092A4 (fr) Compositions de conjugués d'acides nucléiques ciblés
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA54521A (fr) Dérivés d'oxopyridine substitués
EP3426242A4 (fr) Icaritine et dérivés d'icaritine
EP3416647A4 (fr) Iminopyrimidinones substituées par n3 à titre d'agents antipaludéens
EP3820980A4 (fr) Compositions d'esterquats
EP3408254A4 (fr) Sels de l'acide 5-aminolévulinique et dérivés
EP3600279A4 (fr) Formulations d'acide 1-amino-1-cyclopropanecaboxylique
EP3302061A4 (fr) Compositions d'urée à libération prolongée
MA49704A (fr) Dérivés d'acide biliaire à marquage isotopique
EP3600280A4 (fr) Formulations de chlorhydrate d'acide 1-amino-1-cyclopropanecarboxylique
EP4043450A4 (fr) Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac
EP3452441A4 (fr) Dérivés d'acide alpha-truxillique et compositions pharmaceutiques associées
EP3645548A4 (fr) Procédés de préparation d'acides biliaires
EP4013441A4 (fr) Formulations de larazotide
EP3316677A4 (fr) Activateur de passage d'acide jasmonique
EP3955910A4 (fr) Formulations à libération prolongée
EP3444345A4 (fr) Dérivé d'arnmicro-143
EP3377111A4 (fr) Promédicaments d'amine de composés pharmaceutiques
EP3681950A4 (fr) Pulvérisation d'acide tranexamique pour arthroplastie du genou
MA56504A (fr) Dérivés de pyridin-3-yle